The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses findings from the Phase I/II BRUIN trial (NCT03740529), investigating the efficacy of the reversible BTK inhibitor (BTKi) pirtobrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). The trial showed promising preliminary efficacy of this drug, with a 50% overall response rate (ORR) and median progression-free survival (PFS) of 15.6 months in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics/Janssen, TG Therapeutics, AstraZeneca, Caribou Biosciences, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Epizyme, ADC Therapeutics, BeiGene, Morphosys, Bristol Myers Squibb, Merck, Abbvie; Research Funding: Pharmacyclics/Janssen, Sunesis Pharmaceuticals, Nurix, AstraZeneca, Fate Therapeutics, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Curis, Inc, Epizyme, CRISPR Therapeutics, Bristol Myers Squibb, Merck, Adaptive Biotechnologies; Speakers Bureau: TG Therapeutics, AstraZeneca, Kite, Bristol Myers Squibb.
